BioCentury | Aug 13, 2020
Regulation

Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more

...Inc. (NASDAQ:FENC; TSX:FRX) received a complete response letter from FDA for its NDA for Pedmark sodium thiosulfate...
...3BCMA (TNFRSF17; CD269) – Tumor necrosis factor receptor superfamily member 17OX40L (CD134L) – OX40 ligand BC Staff STS, sodium thiosulfate...
BioCentury | Apr 14, 2020
Product Development

April 13 Quick Takes: AZ’s Phase III of Tagrisso unblinded early; plus BeiGene’s tislelizumab and Fennec’s Pedmark

...and granted Priority Review to an NDA from Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX:FRX) for Pedmark sodium thiosulfate...
BioCentury | Dec 8, 2017
Clinical News

Fennec's Pedmark meets in Phase III to prevent hearing loss associated with platinum-based chemotherapies

...Phase III SIOPEL 6 trial in 99 children receiving platinum-based chemotherapies showing that Pedmark (STS, sodium thiosulfate...
...NASDAQ:FENC), Research Triangle Park, N.C. Product: Pedmark (STS, sodium thiosulfate) Business: Otologic Molecular target: NA Description: Sodium thiosulfate...
...patients carrying or not carrying 2 key gene mutations Status: Phase III data Milestone: NA Claire Quang sodium thiosulfate Fennec...
BioCentury | Jul 7, 2017
Financial News

Fennec completes $7.6M private placement

...$4 in a private placement to Essetifin and venBio Select Advisor and other investors. Fennec’s sodium thiosulfate...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...anterior uveitis Ph III data; submit NDA 1Q17; late 2017 Fennec Pharmaceuticals Inc. (TSX:FRX; OTCQB:FENCF) Sodium thiosulfate...
BioCentury | Aug 13, 2015
Tools & Techniques

Helping Beethoven hear

...companies have disclosed compounds for congenital forms of hearing loss. Fennec Pharmaceuticals Inc. (TSX:FRX; OTCQB:FENCF) Sodium thiosulfate...
BioCentury | Jun 8, 2015
Clinical News

Sodium thiosulfate: Interim Phase III data

...OTCQB:FENCF), Research Triangle Park, N.C. Product: Sodium thiosulfate (STS) Business: Other Molecular target: Not available Description: Sodium thiosulfate...
BioCentury | Feb 26, 2015
Translation in Brief

Hearing after cisplatin

...are developing treatments to preserve hearing during chemotherapy. Fennec Pharmaceuticals Inc. has the small molecule sodium thiosulfate...
BioCentury | Feb 16, 2015
Clinical News

Sodium thiosulfate: Phase III ongoing

...OTCQB:FENCF), Research Triangle Park, N.C. Product: Sodium thiosulfate (STS) Business: Other Molecular target: Not available Description: Sodium thiosulfate...
BioCentury | Sep 29, 2014
Emerging Company Profile

Oricula: Preserving hearing

...other companies have therapeutics in development to prevent chemotherapy-induced hearing loss. Fennec Pharmaceuticals Inc. 's sodium thiosulfate...
Items per page:
1 - 10 of 25